- Investing Ideas
- South Korean Pharmaceuticals & Biotech Healthy potentially undervalued
South Korean Pharmaceuticals & Biotech Healthy potentially undervalued
Results
7
Companies which are potentially undervalued and in an acceptable financial position.
7 companies
Dong-A Socio Holdings
Market Cap: ₩540.9b
Engages in the pharmaceutical business in South Korea.
A000640
₩81,600.00
7D
4.6%
1Y
-28.2%
Hugel
Market Cap: ₩3.0t
Develops and manufactures biopharmaceuticals in South Korea and internationally.
A145020
₩274,500.00
7D
5.8%
1Y
-24.9%
Dong-A ST
Market Cap: ₩331.1b
Develops, manufactures, and markets pharmaceutical products in South Korea and internationally.
A170900
₩34,450.00
7D
1.6%
1Y
-26.0%
Daewoong Pharmaceutical
Market Cap: ₩1.4t
Develops, manufactures and commercializes pharmaceutical products in South Korea and internationally.
A069620
₩118,300.00
7D
3.4%
1Y
-18.6%
PharmaResearch
Market Cap: ₩3.8t
Operates as a biopharmaceutical company primarily in South Korea.
A214450
₩366,500.00
7D
20.4%
1Y
-22.0%
Hanmi Pharm
Market Cap: ₩5.4t
A biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally.
A128940
₩422,000.00
7D
4.7%
1Y
46.0%
ST PharmLtd
Market Cap: ₩2.7t
Provides manufacturing services for active pharmaceutical ingredient and intermediate.
A237690
₩131,600.00
7D
8.8%
1Y
52.7%